ID   CDK13_HUMAN             Reviewed;        1512 AA.
AC   Q14004; Q53G78; Q6DKQ9; Q75MH4; Q75MH5; Q96JN4; Q9H4A0; Q9H4A1; Q9UDR4;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 2.
DT   12-OCT-2022, entry version 209.
DE   RecName: Full=Cyclin-dependent kinase 13;
DE            EC=2.7.11.22;
DE            EC=2.7.11.23;
DE   AltName: Full=CDC2-related protein kinase 5;
DE   AltName: Full=Cell division cycle 2-like protein kinase 5;
DE   AltName: Full=Cell division protein kinase 13;
DE            Short=hCDK13;
DE   AltName: Full=Cholinesterase-related cell division controller;
GN   Name=CDK13; Synonyms=CDC2L, CDC2L5, CHED, KIAA1791;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS LEU-700 AND
RP   MET-1170.
RC   TISSUE=Placenta;
RX   PubMed=11162436; DOI=10.1006/bbrc.2000.4042;
RA   Marques F., Moreau J.L., Peaucellier G., Lozano J.C., Schatt P., Picard A.,
RA   Callebaut I., Perre E., Geneviere A.M.;
RT   "A new subfamily of high molecular mass CDC2-related kinases with
RT   PITAI/VRE.";
RL   Biochem. Biophys. Res. Commun. 279:832-837(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-356; PHE-403; GLN-410;
RP   ALA-500; GLY-624 AND MET-1062.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 361-1078, FUNCTION, AND VARIANT LEU-700.
RC   TISSUE=Glioblastoma;
RX   PubMed=1731328; DOI=10.1073/pnas.89.2.579;
RA   Lapidot-Lifson Y., Patinkin D., Prody C.A., Ehrlich G., Seidman S.,
RA   Ben-Aziz R., Benseler F., Eckstein F., Zakut H., Soreq H.;
RT   "Cloning and antisense oligodeoxynucleotide inhibition of a human homolog
RT   of cdc2 required in hematopoiesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:579-583(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 856-1512 (ISOFORM 2).
RC   TISSUE=Thyroid;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 860-1512 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1246, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH C1QBP.
RX   PubMed=16721827; DOI=10.1002/jcb.20986;
RA   Even Y., Durieux S., Escande M.L., Lozano J.C., Peaucellier G., Weil D.,
RA   Geneviere A.M.;
RT   "CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-
RT   associated protein p32 and affects splicing in vivo.";
RL   J. Cell. Biochem. 99:890-904(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HIV-1 TAT (MICROBIAL INFECTION).
RX   PubMed=18480452; DOI=10.1128/jvi.02543-07;
RA   Berro R., Pedati C., Kehn-Hall K., Wu W., Klase Z., Even Y.,
RA   Geneviere A.M., Ammosova T., Nekhai S., Kashanchi F.;
RT   "CDK13, a new potential human immunodeficiency virus type 1 inhibitory
RT   factor regulating viral mRNA splicing.";
RL   J. Virol. 82:7155-7166(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1246, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315; SER-317; SER-325;
RP   SER-340; SER-342; SER-383; SER-395; SER-397; SER-400; SER-437; SER-439 AND
RP   THR-871, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1048, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-556, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20952539; DOI=10.1101/gad.1968210;
RA   Bartkowiak B., Liu P., Phatnani H.P., Fuda N.J., Cooper J.J., Price D.H.,
RA   Adelman K., Lis J.T., Greenleaf A.L.;
RT   "CDK12 is a transcription elongation-associated CTD kinase, the metazoan
RT   ortholog of yeast Ctk1.";
RL   Genes Dev. 24:2303-2316(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383; SER-437; SER-439;
RP   SER-525 AND THR-871, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   RNA EDITING OF POSITION 103.
RX   PubMed=21835166; DOI=10.1016/j.bbrc.2011.07.075;
RA   Maas S., Godfried Sie C.P., Stoev I., Dupuis D.E., Latona J., Porman A.M.,
RA   Evans B., Rekawek P., Kluempers V., Mutter M., Gommans W.M., Lopresti D.;
RT   "Genome-wide evaluation and discovery of vertebrate A-to-I RNA editing
RT   sites.";
RL   Biochem. Biophys. Res. Commun. 412:407-412(2011).
RN   [23]
RP   INTERACTION WITH CCNK.
RX   PubMed=22012619; DOI=10.1101/gad.16962311;
RA   Blazek D., Kohoutek J., Bartholomeeusen K., Johansen E., Hulinkova P.,
RA   Luo Z., Cimermancic P., Ule J., Peterlin B.M.;
RT   "The Cyclin K/Cdk12 complex maintains genomic stability via regulation of
RT   expression of DNA damage response genes.";
RL   Genes Dev. 25:2158-2172(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315; SER-317; SER-383;
RP   SER-395; SER-397; SER-400; SER-437; SER-439; THR-871 AND THR-1246, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315; SER-317; SER-325;
RP   SER-358; SER-360; SER-383; SER-437; SER-439; SER-525; THR-588; THR-871;
RP   SER-1048 AND THR-1246, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-519 AND LYS-547, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   INTERACTION WITH HHV-1 TRANSCRIPTIONAL REGULATOR ICP22 (MICROBIAL
RP   INFECTION).
RX   PubMed=34696162; DOI=10.3390/vaccines9101054;
RA   Isa N.F., Bensaude O., Aziz N.C., Murphy S.;
RT   "HSV-1 ICP22 Is a Selective Viral Repressor of Cellular RNA Polymerase II-
RT   Mediated Transcription Elongation.";
RL   Vaccines (Basel) 9:0-0(2021).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-494; ALA-500; ARG-670 AND MET-1170.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [30]
RP   INVOLVEMENT IN CHDFIDD, AND VARIANTS CHDFIDD ARG-714; ARG-717; GLN-751 AND
RP   SER-842.
RX   PubMed=27479907; DOI=10.1038/ng.3627;
RG   INTERVAL Study;
RG   UK10K Consortium;
RG   Deciphering Developmental Disorders Study;
RA   Sifrim A., Hitz M.P., Wilsdon A., Breckpot J., Turki S.H., Thienpont B.,
RA   McRae J., Fitzgerald T.W., Singh T., Swaminathan G.J., Prigmore E.,
RA   Rajan D., Abdul-Khaliq H., Banka S., Bauer U.M., Bentham J., Berger F.,
RA   Bhattacharya S., Bu'Lock F., Canham N., Colgiu I.G., Cosgrove C., Cox H.,
RA   Daehnert I., Daly A., Danesh J., Fryer A., Gewillig M., Hobson E., Hoff K.,
RA   Homfray T., Kahlert A.K., Ketley A., Kramer H.H., Lachlan K., Lampe A.K.,
RA   Louw J.J., Manickara A.K., Manase D., McCarthy K.P., Metcalfe K., Moore C.,
RA   Newbury-Ecob R., Omer S.O., Ouwehand W.H., Park S.M., Parker M.J.,
RA   Pickardt T., Pollard M.O., Robert L., Roberts D.J., Sambrook J.,
RA   Setchfield K., Stiller B., Thornborough C., Toka O., Watkins H.,
RA   Williams D., Wright M., Mital S., Daubeney P.E., Keavney B., Goodship J.,
RA   Abu-Sulaiman R.M., Klaassen S., Wright C.F., Firth H.V., Barrett J.C.,
RA   Devriendt K., FitzPatrick D.R., Brook J.D., Hurles M.E.;
RT   "Distinct genetic architectures for syndromic and nonsyndromic congenital
RT   heart defects identified by exome sequencing.";
RL   Nat. Genet. 48:1060-1065(2016).
RN   [31]
RP   VARIANTS CHDFIDD GLU-734; ASP-842 AND SER-842.
RX   PubMed=28807008; DOI=10.1186/s13073-017-0463-8;
RA   Bostwick B.L., McLean S., Posey J.E., Streff H.E., Gripp K.W., Blesson A.,
RA   Powell-Hamilton N., Tusi J., Stevenson D.A., Farrelly E., Hudgins L.,
RA   Yang Y., Xia F., Wang X., Liu P., Walkiewicz M., McGuire M., Grange D.K.,
RA   Andrews M.V., Hummel M., Madan-Khetarpal S., Infante E., Coban-Akdemir Z.,
RA   Miszalski-Jamka K., Jefferies J.L., Rosenfeld J.A., Emrick L., Nugent K.M.,
RA   Lupski J.R., Belmont J.W., Lee B., Lalani S.R.;
RT   "Phenotypic and molecular characterisation of CDK13-related congenital
RT   heart defects, dysmorphic facial features and intellectual developmental
RT   disorders.";
RL   Genome Med. 9:73-73(2017).
CC   -!- FUNCTION: Cyclin-dependent kinase which displays CTD kinase activity
CC       and is required for RNA splicing. Has CTD kinase activity by
CC       hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of
CC       the largest RNA polymerase II subunit RPB1, thereby acting as a key
CC       regulator of transcription elongation. Required for RNA splicing,
CC       probably by phosphorylating SRSF1/SF2. Required during hematopoiesis.
CC       In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein
CC       acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA
CC       splicing and promoting the production of the doubly spliced HIV-1
CC       protein Nef. {ECO:0000269|PubMed:16721827, ECO:0000269|PubMed:1731328,
CC       ECO:0000269|PubMed:18480452, ECO:0000269|PubMed:20952539}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[DNA-directed RNA polymerase] + ATP = ADP + H(+) + phospho-
CC         [DNA-directed RNA polymerase]; Xref=Rhea:RHEA:10216, Rhea:RHEA-
CC         COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546,
CC         ChEBI:CHEBI:456216; EC=2.7.11.23;
CC         Evidence={ECO:0000269|PubMed:20952539};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC         Evidence={ECO:0000269|PubMed:20952539};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.22; Evidence={ECO:0000269|PubMed:20952539};
CC   -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 1
CC       (HHV-1) transcriptional regulator ICP22. {ECO:0000269|PubMed:34696162}.
CC   -!- SUBUNIT: Interacts with CCNL1 and CCNL2 (By similarity). Interacts with
CC       CCNK. Interacts with C1QBP. {ECO:0000250, ECO:0000269|PubMed:16721827,
CC       ECO:0000269|PubMed:22012619}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Tat.
CC       {ECO:0000269|PubMed:18480452}.
CC   -!- INTERACTION:
CC       Q14004; O75909: CCNK; NbExp=7; IntAct=EBI-968626, EBI-739806;
CC       Q14004; Q16543: CDC37; NbExp=2; IntAct=EBI-968626, EBI-295634;
CC       Q14004-2; Q07021: C1QBP; NbExp=6; IntAct=EBI-6375898, EBI-347528;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000269|PubMed:16721827}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14004-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14004-2; Sequence=VSP_013579;
CC   -!- TISSUE SPECIFICITY: Expressed in fetal brain, liver, muscle and in
CC       adult brain. Also expressed in neuroblastoma and glioblastoma tumors.
CC   -!- RNA EDITING: Modified_positions=103 {ECO:0000269|PubMed:21835166};
CC       Note=Edited at about 88%.;
CC   -!- DISEASE: Congenital heart defects, dysmorphic facial features, and
CC       intellectual developmental disorder (CHDFIDD) [MIM:617360]: An
CC       autosomal dominant syndrome characterized by atrial and/or ventricular
CC       septal congenital heart defects, facial dysmorphism with hypertelorism,
CC       upslanted palpebral fissures, epicanthal folds, ptosis, strabismus,
CC       posteriorly rotated ears, thin upper lip, and small mouth. Patients
CC       manifest global developmental delay, delayed walking and speech
CC       acquisition, and intellectual disability. Some patients have mild
CC       microcephaly, a small cerebral cortex, and agenesis of corpus callosum.
CC       More variable features include clinodactyly and/or camptodactyly of the
CC       fingers, hypotonia, and joint hypermobility.
CC       {ECO:0000269|PubMed:27479907, ECO:0000269|PubMed:28807008}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA58424.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAS07490.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc2l5/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ297709; CAC10400.1; -; mRNA.
DR   EMBL; AJ297710; CAC10401.1; -; mRNA.
DR   EMBL; AY679523; AAT74623.1; -; Genomic_DNA.
DR   EMBL; AC072061; AAS07490.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC072061; AAS07491.1; -; Genomic_DNA.
DR   EMBL; AC006023; AAD54514.1; -; Genomic_DNA.
DR   EMBL; M80629; AAA58424.1; ALT_FRAME; mRNA.
DR   EMBL; AK223053; BAD96773.1; -; mRNA.
DR   EMBL; AB058694; BAB47420.1; -; mRNA.
DR   CCDS; CCDS5461.1; -. [Q14004-1]
DR   CCDS; CCDS5462.1; -. [Q14004-2]
DR   PIR; A38197; A38197.
DR   RefSeq; NP_003709.3; NM_003718.4. [Q14004-1]
DR   RefSeq; NP_112557.2; NM_031267.3. [Q14004-2]
DR   PDB; 5EFQ; X-ray; 2.00 A; A/C=694-1039.
DR   PDB; 7NXJ; X-ray; 2.36 A; A/C=694-1039.
DR   PDBsum; 5EFQ; -.
DR   PDBsum; 7NXJ; -.
DR   AlphaFoldDB; Q14004; -.
DR   SMR; Q14004; -.
DR   BioGRID; 114176; 115.
DR   ComplexPortal; CPX-359; Cyclin K-CDK13 complex.
DR   IntAct; Q14004; 58.
DR   MINT; Q14004; -.
DR   STRING; 9606.ENSP00000181839; -.
DR   BindingDB; Q14004; -.
DR   ChEMBL; CHEMBL1795192; -.
DR   GuidetoPHARMACOLOGY; 1966; -.
DR   GlyGen; Q14004; 6 sites, 2 O-linked glycans (6 sites).
DR   iPTMnet; Q14004; -.
DR   PhosphoSitePlus; Q14004; -.
DR   BioMuta; CDK13; -.
DR   DMDM; 66774048; -.
DR   EPD; Q14004; -.
DR   jPOST; Q14004; -.
DR   MassIVE; Q14004; -.
DR   MaxQB; Q14004; -.
DR   PaxDb; Q14004; -.
DR   PeptideAtlas; Q14004; -.
DR   PRIDE; Q14004; -.
DR   ProteomicsDB; 59786; -. [Q14004-1]
DR   ProteomicsDB; 59787; -. [Q14004-2]
DR   Antibodypedia; 26726; 207 antibodies from 27 providers.
DR   DNASU; 8621; -.
DR   Ensembl; ENST00000181839.10; ENSP00000181839.4; ENSG00000065883.17. [Q14004-1]
DR   Ensembl; ENST00000340829.10; ENSP00000340557.5; ENSG00000065883.17. [Q14004-2]
DR   GeneID; 8621; -.
DR   KEGG; hsa:8621; -.
DR   MANE-Select; ENST00000181839.10; ENSP00000181839.4; NM_003718.5; NP_003709.3.
DR   UCSC; uc003thh.5; human. [Q14004-1]
DR   CTD; 8621; -.
DR   DisGeNET; 8621; -.
DR   GeneCards; CDK13; -.
DR   GeneReviews; CDK13; -.
DR   HGNC; HGNC:1733; CDK13.
DR   HPA; ENSG00000065883; Low tissue specificity.
DR   MalaCards; CDK13; -.
DR   MIM; 603309; gene.
DR   MIM; 617360; phenotype.
DR   neXtProt; NX_Q14004; -.
DR   OpenTargets; ENSG00000065883; -.
DR   PharmGKB; PA26264; -.
DR   VEuPathDB; HostDB:ENSG00000065883; -.
DR   eggNOG; KOG0600; Eukaryota.
DR   GeneTree; ENSGT00940000157852; -.
DR   HOGENOM; CLU_004166_3_0_1; -.
DR   InParanoid; Q14004; -.
DR   OrthoDB; 925637at2759; -.
DR   PhylomeDB; Q14004; -.
DR   TreeFam; TF101060; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   BRENDA; 2.7.11.23; 2681.
DR   PathwayCommons; Q14004; -.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; Q14004; -.
DR   SIGNOR; Q14004; -.
DR   BioGRID-ORCS; 8621; 67 hits in 1112 CRISPR screens.
DR   ChiTaRS; CDK13; human.
DR   GeneWiki; CDC2L5; -.
DR   GenomeRNAi; 8621; -.
DR   Pharos; Q14004; Tchem.
DR   PRO; PR:Q14004; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q14004; protein.
DR   Bgee; ENSG00000065883; Expressed in buccal mucosa cell and 211 other tissues.
DR   ExpressionAtlas; Q14004; baseline and differential.
DR   Genevisible; Q14004; HS.
DR   GO; GO:0002945; C:cyclin K-CDK13 complex; IPI:MGI.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IBA:GO_Central.
DR   GO; GO:0008024; C:cyclin/CDK positive transcription elongation factor complex; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0019908; C:nuclear cyclin-dependent protein kinase holoenzyme complex; ISS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0030332; F:cyclin binding; IPI:MGI.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IDA:UniProtKB.
DR   GO; GO:0000380; P:alternative mRNA splicing, via spliceosome; ISS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IMP:UniProtKB.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0070816; P:phosphorylation of RNA polymerase II C-terminal domain; IDA:UniProtKB.
DR   GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IDA:ComplexPortal.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0009966; P:regulation of signal transduction; IDA:ComplexPortal.
DR   GO; GO:0006368; P:transcription elongation by RNA polymerase II promoter; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Disease variant; Host-virus interaction; Intellectual disability;
KW   Isopeptide bond; Kinase; mRNA processing; mRNA splicing;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   RNA editing; Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..1512
FT                   /note="Cyclin-dependent kinase 13"
FT                   /id="PRO_0000085711"
FT   DOMAIN          705..998
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..20
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          30..60
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          75..545
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          566..596
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          654..685
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1025..1084
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1138..1170
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1201..1231
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1245..1273
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1379..1400
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1468..1512
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        39..60
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        190..205
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        218..244
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        245..269
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        270..319
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        327..347
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        362..410
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        411..433
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        434..451
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        487..511
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        569..592
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1052..1081
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1140..1170
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1468..1499
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        837
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         711..719
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         734
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         315
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         317
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         340
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         342
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         358
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         360
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         400
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         437
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         556
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         588
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         871
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1048
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1058
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q69ZA1"
FT   MOD_RES         1246
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        519
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        547
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1079..1138
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11162436, ECO:0000303|Ref.5"
FT                   /id="VSP_013579"
FT   VARIANT         103
FT                   /note="Q -> R (in RNA edited version)"
FT                   /id="VAR_066526"
FT   VARIANT         340
FT                   /note="S -> F (in dbSNP:rs13622)"
FT                   /id="VAR_053926"
FT   VARIANT         356
FT                   /note="P -> A (in dbSNP:rs17537669)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022381"
FT   VARIANT         403
FT                   /note="L -> F (in dbSNP:rs3735137)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022382"
FT   VARIANT         410
FT                   /note="R -> Q (in dbSNP:rs17496261)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022383"
FT   VARIANT         494
FT                   /note="T -> A (in dbSNP:rs34624759)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041965"
FT   VARIANT         500
FT                   /note="T -> A (in dbSNP:rs3735135)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.2"
FT                   /id="VAR_022384"
FT   VARIANT         624
FT                   /note="S -> G (in dbSNP:rs17496275)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022385"
FT   VARIANT         670
FT                   /note="T -> R (in dbSNP:rs34775357)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041966"
FT   VARIANT         700
FT                   /note="R -> L (in dbSNP:rs1057000)"
FT                   /evidence="ECO:0000269|PubMed:11162436,
FT                   ECO:0000269|PubMed:1731328"
FT                   /id="VAR_022386"
FT   VARIANT         714
FT                   /note="G -> R (in CHDFIDD; dbSNP:rs1057519633)"
FT                   /evidence="ECO:0000269|PubMed:27479907"
FT                   /id="VAR_078598"
FT   VARIANT         717
FT                   /note="G -> R (in CHDFIDD; dbSNP:rs1057519632)"
FT                   /evidence="ECO:0000269|PubMed:27479907"
FT                   /id="VAR_078599"
FT   VARIANT         734
FT                   /note="K -> E (in CHDFIDD; dbSNP:rs1064795731)"
FT                   /evidence="ECO:0000269|PubMed:28807008"
FT                   /id="VAR_079422"
FT   VARIANT         751
FT                   /note="R -> Q (in CHDFIDD; dbSNP:rs1057519634)"
FT                   /evidence="ECO:0000269|PubMed:27479907"
FT                   /id="VAR_078600"
FT   VARIANT         842
FT                   /note="N -> D (in CHDFIDD; dbSNP:rs1554333853)"
FT                   /evidence="ECO:0000269|PubMed:28807008"
FT                   /id="VAR_079423"
FT   VARIANT         842
FT                   /note="N -> S (in CHDFIDD; dbSNP:rs878853160)"
FT                   /evidence="ECO:0000269|PubMed:27479907,
FT                   ECO:0000269|PubMed:28807008"
FT                   /id="VAR_078601"
FT   VARIANT         1062
FT                   /note="V -> M (in dbSNP:rs17496712)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022387"
FT   VARIANT         1170
FT                   /note="V -> M (in dbSNP:rs3204309)"
FT                   /evidence="ECO:0000269|PubMed:11162436,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041967"
FT   CONFLICT        21
FT                   /note="K -> R (in Ref. 1; CAC10400/CAC10401)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        671
FT                   /note="A -> T (in Ref. 1; CAC10400/CAC10401 and 4;
FT                   AAA58424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        810
FT                   /note="N -> Y (in Ref. 4; AAA58424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        862..866
FT                   /note="YSSEE -> FSVFF (in Ref. 5; BAB47420)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1180
FT                   /note="Q -> R (in Ref. 5; BAD96773)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1356
FT                   /note="G -> E (in Ref. 5; BAD96773)"
FT                   /evidence="ECO:0000305"
FT   HELIX           702..704
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          705..713
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          715..724
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   TURN            725..727
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          730..736
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          739..741
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           747..758
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          767..772
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          787..792
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          795..797
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           798..804
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           811..830
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           840..842
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          843..845
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          851..853
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           856..858
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          864..866
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           877..879
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           882..885
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           894..908
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   STRAND          909..911
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           919..930
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   TURN            935..937
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           939..943
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   TURN            945..950
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           960..963
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   TURN            964..966
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           969..978
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   TURN            983..985
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           989..994
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   TURN            996..1000
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           1003..1005
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           1019..1024
FT                   /evidence="ECO:0007829|PDB:5EFQ"
FT   HELIX           1026..1030
FT                   /evidence="ECO:0007829|PDB:5EFQ"
SQ   SEQUENCE   1512 AA;  164923 MW;  3CA54A3585A2943D CRC64;
     MPSSSDTALG GGGGLSWAEK KLEERRKRRR FLSPQQPPLL LPLLQPQLLQ PPPPPPPLLF
     LAAPGTAAAA AAAAAASSSC FSPGPPLEVK RLARGKRRAG GRQKRRRGPR AGQEAEKRRV
     FSLPQPQQDG GGGASSGGGV TPLVEYEDVS SQSEQGLLLG GASAATAATA AGGTGGSGGS
     PASSSGTQRR GEGSERRPRR DRRSSSGRSK ERHREHRRRD GQRGGSEASK SRSRHSHSGE
     ERAEVAKSGS SSSSGGRRKS ASATSSSSSS RKDRDSKAHR SRTKSSKEPP SAYKEPPKAY
     REDKTEPKAY RRRRSLSPLG GRDDSPVSHR ASQSLRSRKS PSPAGGGSSP YSRRLPRSPS
     PYSRRRSPSY SRHSSYERGG DVSPSPYSSS SWRRSRSPYS PVLRRSGKSR SRSPYSSRHS
     RSRSRHRLSR SRSRHSSISP STLTLKSSLA AELNKNKKAR AAEAARAAEA AKAAEATKAA
     EAAAKAAKAS NTSTPTKGNT ETSASASQTN HVKDVKKIKI EHAPSPSSGG TLKNDKAKTK
     PPLQVTKVEN NLIVDKATKK AVIVGKESKS AATKEESVSL KEKTKPLTPS IGAKEKEQHV
     ALVTSTLPPL PLPPMLPEDK EADSLRGNIS VKAVKKEVEK KLRCLLADLP LPPELPGGDD
     LSKSPEEKKT ATQLHSKRRP KICGPRYGET KEKDIDWGKR CVDKFDIIGI IGEGTYGQVY
     KARDKDTGEM VALKKVRLDN EKEGFPITAI REIKILRQLT HQSIINMKEI VTDKEDALDF
     KKDKGAFYLV FEYMDHDLMG LLESGLVHFN ENHIKSFMRQ LMEGLDYCHK KNFLHRDIKC
     SNILLNNRGQ IKLADFGLAR LYSSEESRPY TNKVITLWYR PPELLLGEER YTPAIDVWSC
     GCILGELFTK KPIFQANQEL AQLELISRIC GSPCPAVWPD VIKLPYFNTM KPKKQYRRKL
     REEFVFIPAA ALDLFDYMLA LDPSKRCTAE QALQCEFLRD VEPSKMPPPD LPLWQDCHEL
     WSKKRRRQKQ MGMTDDVSTI KAPRKDLSLG LDDSRTNTPQ GVLPSSQLKS QGSSNVAPVK
     TGPGQHLNHS ELAILLNLLQ SKTSVNMADF VQVLNIKVNS ETQQQLNKIN LPAGILATGE
     KQTDPSTPQQ ESSKPLGGIQ PSSQTIQPKV ETDAAQAAVQ SAFAVLLTQL IKAQQSKQKD
     VLLEERENGS GHEASLQLRP PPEPSTPVSG QDDLIQHQDM RILELTPEPD RPRILPPDQR
     PPEPPEPPPV TEEDLDYRTE NQHVPTTSSS LTDPHAGVKA ALLQLLAQHQ PQDDPKREGG
     IDYQAGDTYV STSDYKDNFG SSSFSSAPYV SNDGLGSSSA PPLERRSFIG NSDIQSLDNY
     STASSHSGGP PQPSAFSESF PSSVAGYGDI YLNAGPMLFS GDKDHRFEYS HGPIAVLANS
     SDPSTGPEST HPLPAKMHNY NYGGNLQENP SGPSLMHGQT WTSPAQGPGY SQGYRGHIST
     STGRGRGRGL PY
//
